Societal impact abstract: This research focuses on radiopharmaceuticals, a class of medical product increasingly used in clinical care, particularly for cancer treatment. The findings of this study may have implications for the healthcare system by contributing to the development of personalized dosimetry. By enabling more tailored and precise administration of targeted radionuclide therapy, this work contributes to optimizing treatment efficacy and minimizing side effects. Ultimately, this can enhance therapeutic outcomes and improve the quality of life for cancer patients. However, implementing personalized dosimetry requires additional medical imaging, which could put extra pressure on already busy imaging departments in hospitals. This may lead to increased demand for medical staff and specialized equipment. Currently, most health insurance systems only reimburse one scan per treatment. If this policy remains unchanged, patients may need to pay out-of-pocket for additional scans, something that is not financially feasible for everyone. Therefore, changes in how dosimetry is performed could also require adjustments to health insurance reimbursement policies. Lastly, this research may also influence the pharmaceutical and medical technology industries, which manufacture the components needed for these advanced therapies.